Your browser is old and is not supported. Upgrade for better security.

Invest in Amnion Life LLC

Amniobed is the first step towards an artificial womb for preterm infants

Pitch Video
Investor Panel

Highlights

1
In Amniobed, the preterm infant is partially submerged in synthetic amniotic fluid.
2
Amniobed is intended to prevent hypothermia in preterm infants and decrease environmental heat loss.
3
Hypothermia leads to poor medical outcomes and an increased chance of infant death.
4
Strong patent portfolio with multiple patents in the US, China, and Japan and pending in Europe.
5
Studies have shown 40% of infants admitted to the NICU from L&D are hypothermic in 1st hour of life.
6
Significant calorie loss in the NICU leads to diminished weight gain and longer hospital stays
7
3 Years of R&D. Designed, sourced, procured, and assembled Amniobed Golden Hour plus software.
8
The project was placed on pause in 2020 due to COVID-19. Raising capital to finish the prototype.

Our Team

A little girl in our family was born extreme preterm and spent months in the NICU.  Complications from her preterm birth led to life long neurodevelopmental and ocular injuries.  Soon after seeing her, I had a dream that preterm infants suffer and need a fluid environment life similar to their mother's womb. I soon became obsessed and passionate.


Giving premature infants a better chance at life

Amnion Life LLC has the mission to develop novel devices to decrease mortality & complications in preterm infants. As part of its mission, Amnion Life is developing the Amniobed™ - a novel, patent-protected1
, neonatal incubator system intended to recreate the core conditions of an in- womb environment. Amniobed can provide a more natural incubator environment for continuous critical organ development, improve preterm infants' thermoregulation and fluid management, and help prevent hypothermia in critical care settings.

Reasons to Invest

  • Protected by multiple issued patents in the US, China, Japan, and pending in Europe.
  • Successful earlier rounds of over $1.8M in investment and crowdfunding.
  • Lead by our founder Amir Fassihi, M.D., an experienced neuroradiologist, our team is made up of experts in regulatory matters (particularly applications to the FDA), medical device commercialization and roll-outs, QMS implementations, and European regulatory affairs.


Giving premature infants a better chance at life

At Amnion Life, our mission is to develop novel devices to decrease mortality & complications in preterm infants.

Our patent-protected flagship product[, the AmnioBed™[1] is a neonatal incubator system utilizing a proprietary, synthetic amniotic fluid, intended to create an environment that more closely resembles a mother’s womb to encourage ongoing, and critical development. The technology is designed to protect, hydrate, and nourish these vulnerable newborns, providing safety and comfort during their most sensitive, vital hours.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.


THE PROBLEM

Premature birth is the #1 cause of infant mortality across the globe

In the United States and across the world, one out of every ten infants born is preterm —and each and everyone requires immediate attention.[2]According to the World Health Organization, premature birth is the leading cause of death for children under five years old across the globe.[3]For those who do survive early infanthood, inadequate treatment in the first days and weeks of life can put them at risk of long-term health problems, leading to a lifetime of emotional and financial challenges.[4]

[6]

Preemies, due to their heightened sensitivity, are very susceptible to heat loss, resulting in possible hypothermia and dehydration. This, in turn, can introduce other ailments such as weight loss, brain hemorrhage, hypoglycemia, and sepsis. In the first critical hour of a preterm infant’s life, he or she is at significant risk of what is called ”transitional hypothermia.” [7]

An infant may ultimately end up spending over 100 days in the NICU.[8] The overall impact can be devastating, and current health technologies for addressing the issue are inadequate.

THE SOLUTION
Patent-protected technology that keeps preemies safe, warm, and stabilized after birth

The Amniobed is designed to improve health outcomes for preterm infants while also reducing their time spent in the NICU. We’ve created a revolutionary proprietary medical technology that leverages the power of fluid as a source of heat regulation, transfer, and hydration. Designed to replace current incubators, wraps, and warmers, the Amniobed partially surrounds a preterm infant in synthetic amniotic fluid to simulate the womb, thereby easing their transition into the world.

Amniobed™ Golden Hour - is intended to replace the use of radiant warmer/plastic wrap in the labor and delivery room to allow optimal temperature regulation of the infant immediately upon birth and to prevent transitional hypothermia very preterm and extremely preterm infants).

Amniobed™ 24Hour - is intended to replace convection incubators for use in the NICU for up to 28 days. It is intended to improve temperature regulation, fluid management, skin protection and general comfort for preterm infants.

This leads to healthier babies and substantial reductions in both short-term and long-term emotional and financial stress for everyone involved.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.

THE MARKET

Billions of healthcare dollars are spent on preterm infants

The US spends over $26 billion each year on costs associated with premature births.[9]The average cost per day for an infant in the NICU exceeds $3000.[10]Extremely preterm infants can spend 110 days or more in intensive care[11]—earning them the nickname “million-dollar babies.”[12]

There are 985 NICU facilities in the US[13]with 22,721 total beds[14], serving the hundreds of thousands of preterm infants in the US each year. The US is in the world’s top 10 based on its number of premature births, with the overall global estimate for premature births per year tallied at 15 million.[15]

[16]

OUR TRACTION
Award-winning medical innovations

Amnion Life has been thrilled to receive multiple Gold Awards for our flagship Amniobed, including second place in the 2019 Cleveland Clinic AMP’D Arena Medical Innovation Summit and third place in the 2019 UCSF/Stanford Pediatric Device Consortium Competition. We’ve secured multiple issued U.S. utility patents, with several foreign patents pending.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.

This round of funding will enable us to perform pre-clinical verification, usability testing, and pilot studies. The Amniobed will then be ready for clinical trials, FDA and CE mark approval, and from there, manufacturing and commercialization.


WHAT WE DO
We’re building a much better incubator

The Amniobed™ is a rigorously researched and carefully designed incubator that partially submerges the infant in fluid. Our uniquely crafted synthetic fluid mimics a mother's amniotic fluid in temperature, electrolyte balance, pH, and minerals. The Amniobed was conceived with particular consideration to an infant’s first hour of life, at which point they are especially vulnerable. As premature infants make the dramatic transition from amniotic fluid to air, they are at elevated risk of hypothermia and dehydration. Negative outcomes during this first “golden” hour of life are associated with higher incidences of mortality, as well as the development of comorbidities and long-term disabilities.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.

The infant is safely supported by an ergonomic seat and harness, which ensure the head is always above the level of fluid and allow movement of the arms and legs. The infant is also outfitted with a cap that tracks skin temperature and contains an electrocardiogram. A 24/7 audio and video feed connects to a smartphone app for remote observation at all times, allowing the mother and/or other caregivers to talk directly to the baby.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.


THE BUSINESS MODEL

Equipping hospitals across the world with our state-of-the-art Amniobed

We are pursuing a model that enables hospitals access to Amniobed either for purchase or lease. We project an average selling price of $150,000 per unit in the US and at a discount in Rest of World, and will also offer a leasing option accompanied by lower upfront costs.

Our model plans to have recurring revenue through a $150-$250 price per use fee for supplies such as the amniotic fluid cartridge and sterile cover. Each Amiobed can be used >300 times per year meaning we can generate greater than $60,000 revenue per device.

Cost of Goods Sold is estimated at $45,000 for parts and $1600 for labor for assembly. The Company estimates approximately $25,000 to $37,500 in costs associated with sales and distribution of each unit and $5000 for shipping and installation.. The costs of goods sold for daily supplies is estimated at $50 per unit use. Total cost for each unit is estimated at $76,600 to $89,100 per unit. Thus the Company estimates margins of 40% on capital equipment costs and margins >70% for supplies.

Regulatory Strategy

We have developed a network of medical device professionals and resources in the Republic of Serbia, Macedonia and Bulgaria. Bulgaria is part of European Union and has a Notified Body. As such,we intend to seek CE Mark approval for marketing and sales of Amniobed Golden Hour and Amniobed 24Hr in Bulgaria.

Once we have regulatory approval for Amniobed Golden Hour in the European Union, we plan to seek distribution partnerships in the EU, followed by distribution partnerships and regulatory applications in U.K, Canada and Australia, followed by Israel, UAE and SA the MIddle East and China, S. Korea and Japan in the Far East. We also intend to design and develop a lower cost Amniobed for India and developing countries.

We intend to submit a Presub Application to the FDA upon reaching Design Freeze and will be in close coordination with the FDA as Amniobed is approved and utilized worldwide. The Real World Data generated is intended to be used to prove safety and efficacy of the device for our application to the FDA.

Similar to Amniobed Golden Hour, Real World Data (ROW) from use of Amniobed 24HR win ROW will be used to prove safety and efficacy of the device to the FDA. Thus, it is expected that FDA approval will lag ROW approval by at least one year.

HOW WE ARE DIFFERENT
Amniobed will be the incubator that recreates a fluid environment

Convection-warmed incubators, which rely on artificial humidification, can take up to one hour to reach optimal temperature and humidity levels. Their incubator ports are opened and closed as often as once an hour, allowing in drafts of cold, dry air and subsequent temperature fluctuation. The box-like design can result in pressure sores and skin injuries, and is not well suited for keeping infants with very low birth weights warm. Radiant warmer beds, on the other hand, distribute heat unevenly across an infant’s body parts and can result in excess evaporative water loss in addition to skin injuries.

Our Amnionbed replaces humidified incubators, plastic wraps, radiant warmers, and chemically heated mattresses with a holistic system that reduces the risk of hypothermia and dehydration. Our fluid-based technology regulates temperature, reduces friction, and enables body movement, all in a safer, more comfortable, and more comforting way.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.


THE VISION
The new standard for intensive care

Amnion Life is ready to revolutionize modern intensive care. Stationed in hospitals across the world, the Amnionbed will transform the quality of care and patient outcomes in the NICU, improving the immediate and long-term health of preterm infants. In doing so, we will be reducing the time, cost, and intense emotional distress associated with drawn-out hospital stays for families and their preemie newborns, as well as hardworking healthcare workers.

But we won’t just stop there. Looking ahead, we’re ready to design and deliver superior outcomes for infant and adult patients alike, with intensive care beds and accompanying technologies built for all critical use cases. Amnioburn, Amniotransport, AmnioICU, will address other areas in need of increased support and technological innovation.

In ten years, we’ll be looking back on today’s incubators and hospital beds and wondering how it took so long for them to earn an upgrade.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.

OUR LEADERSHIP
Medical expertise meets technological know-how

Amir Fassihi: Founder and CEO

A neuroradiologist and entrepreneur, Amir Fassihi is the founder and visionary behind Amnion Life. His dedication to developing this new and innovative incubator was spurred by the experience of witnessing a very preterm birth within his family. The Amnionbed aims to address the many physical and emotional challenges that accompany such early births. The Amnion Life team also includes experts in cutting-edge medical technologies, biomedical engineering, regulatory affairs, and medical device commercialization. In its next phase, Amnion Life will continue to onboard top talent in these fields to supervise the company through its next stages.

WHY INVEST
A commitment to future families

The challenges facing premature infants are here to stay—but we can bring change to our technologies and solutions. We are overdue for a system that ensures better outcomes for the most vulnerable newborns at their most vital hours. We’ve created the Amniobed do just that, and we’d love for you to join us in making an unwavering commitment to future families around the world.

The above is a rendering of a future Amniobed. Images are computer-generated demo versions. The product is still currently under development.

[1] US Patent No. 9,662,257, issued on May 30, 2017

https://patents.google.com/patent/US9662257?oq=US+Patent+No.+9%2c662%2c257%2c+issued+on+May+30%2c+20... Patent No. 10,166,161, issued on January 1, 2019

https://patents.google.com/patent/US10166161B2/en?oq=US+Patent+No.+10%2c166%2c161%2c+issued+on+Janua... Patent No. 201680064293.7 issued January 8, 2020

https://patents.google.com/patent/CN108289780B/en?assignee=Amnion+Life+LLC&oq=Amnion+Life+LLC Patent No. No. 2018-521506 issued August 28th, 2020

https://patents.google.com/patent/JP6755949B2/en?assignee=Amnion+Life+LLC&oq=Amnion+Life+LLC

[2] Retrieved April 03, 2021, from https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm

Content source: Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion

[3] Retrieved from World Health Organization https://www.who.int/news-room/fact-sheets/detail/preterm-birth#:~:text=Key%20facts,and%20this%20numb... L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016;388(10063):3027-35.

(2) Blencowe H, Cousens S, Oestergaard M, Chou D, Moller AB, Narwal R, Adler A, Garcia CV, Rohde S, Say L, Lawn JE. National, regional and worldwide estimates of preterm birth. The Lancet, June 2012. 9;379(9832):2162-72. Estimates from 2010.

[4] Bissinger, Robin L. PhD, APRN, NNP-BC; Annibale, David J. MD Thermoregulation in Very Low-Birth-Weight Infants During the Golden Hour, Advances in Neonatal Care: October 2010 - Volume 10 - Issue 5 - p 230-238

doi: 10.1097/ANC.0b013e3181f0ae63

[5] Source: World Health Organiation https://www.who.int/news-room/fact-sheets/detail/preterm-birth#:~:text=An%20estimated%2015%20million%20babies%20are%20born%20too%20early%20every,of%20preterm%20birth%20(1).&text=Globally%2C%20prematurity%20is%20the%20leading,the%20age%20of%205%20years.

[6] Source: World Health Organiation https://www.who.int/news-room/fact-sheets/detail/preterm-birth#:~:text=An%20estimated%2015%20million%20babies%20are%20born%20too%20early%20every,of%20preterm%20birth%20(1).&text=Globally%2C%20prematurity%20is%20the%20leading,the%20age%20of%205%20years.

[7] Bissinger, Robin L. PhD, APRN, NNP-BC; Annibale, David J. MD Thermoregulation in Very Low-Birth-Weight Infants During the Golden Hour, Advances in Neonatal Care: October 2010 - Volume 10 - Issue 5 - p 230-238

doi: 10.1097/ANC.0b013e3181f0ae63

[8] Florida AHCA Facility Report, 2016

[9] Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE, Butler AS, editors. Preterm Birth: Causes, Consequences, and Prevention. Washington (DC): National Academies Press (US); 2007. 12, Societal Costs of Preterm Birth. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11358/

[10] MANAGED CARE January 2010. © MediMedia USA “How Plans Can Improve Outcomes And Cut Costs for Preterm Infant Care” Michael Kornhauser, MD: Alere Women’s and Children’s Health

Roy Schneiderman, MD : Alere Women’s and Children’s Health

[11] Florida AHCA Facility Report, 2016

[12] Florida AHCA Facility Report, 2016

[13] Vermont Oxford Network https://public.vtoxford.org/

[14] American Hospital Association https://www.aha.org/statistics/fast-facts-us-hospitals

[15] Lancet Glob Health 2018 Published online October 29, 2018 http://dx.doi.org/10.1016/S2214-109X(18)304)30451-0

[16] Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE, Butler AS, editors. Preterm Birth: Causes, Consequences, and Prevention. Washington (DC): National Academies Press (US); 2007. 12, Societal Costs of Preterm Birth. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11358/




Downloads

Overview